A shadow market for unapproved slimming drugs is propelled by social media fitness personalities and sellers on messaging platforms, according to recent findings.
Experimental Treatment Gaining Traction Via Social Media
The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning effects. Followers are encouraged to message these accounts directly for source information, while also obtaining discount codes.
Active Commerce on Social Networks
Separately, a robust market exists on messaging services, where communities with numerous of participants share comparison photos, administration instructions and assertions of next-day British shipping. Sellers promote the substance there before directing customers to other platforms for purchases.
Learning About The Experimental Drug
Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being promoted digitally as the successor to Ozempic.
Healthcare Professionals Voice Concerns
However, physicians and chemists have warned that the distribution of what remains an unapproved medication in the United Kingdom is worrisome and could lead to individuals administering substances of unknown origin.
Some professionals said the popularity for retatrutide could be linked to the rising price of licensed weight loss products such as Mounjaro.
Regulatory Position and Implementation
Selling the unapproved drug on social media or Telegram is illegal in the UK, as it is an unlicensed drug that must not be marketed or distributed for personal consumption under the Human Medicines Regulations 2012.
Several influencers try to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, legal action or imprisonment.
Service Reaction and Content Removal
Based on the social media company, the service has removed problematic material and prohibited associated keywords and search suggestions. The company said it was committed to keeping the service secure and investing in strengthening enforcement strategies.
Digital Trading Operations
Research also discovered groups with up to nine thousand participants selling the experimental drug using Telegram's integrated discovery tool, which functions like a public directory. Entering “retatrutide” instantly displays groups with numerous of users, populated with photos of weight loss, positive reviews and detailed guides for mixing or injecting at home.
Within minutes of entering one group, a seller shared contact information, where most transactions occur. The seller provided an guidebook and promised delivery within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one inquired about body mass, health issues or previous experience.
Product Details and Pricing
Within these groups, messages display dark colored parcels with Royal Mail labels, stating to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Buyers can select between powder vials, mixed at home with sterile water, or pre-filled pens typically priced at 160 pounds for 20mg. When asked how long a injector should last, sellers give conflicting responses varying between a few weeks to “depends on your body”.
Platform Oversight and Security Measures
A spokesperson for Telegram said it regularly monitored harmful material on its service including content that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“People are administering substances they can’t verify. Even if the research behind this drug is valid, these digital versions may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to recent cost increases for approved weight-loss medications such as Mounjaro. “With prices increasing, patients are turning to online platforms. But fake injections are highly dangerous. You cannot know what’s inside or whether the environment they were produced in was sterile,” she explained.
Her staff has already seen individuals injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but buying from Telegram or WhatsApp is gambling with your well-being,” stated Wyllie. “These materials could be impure or incorrectly dosed.”
Manufacturer Position
A representative from the pharmaceutical company said the substance was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they said, adding that any item “falsely representing itself as a company experimental product not yet authorized … may expose users to possibly significant medical dangers”.
